ArticleTranslational gastroenterology and hepatology2026
Exploring the association between gut microbiota metabolites and hepatocellular carcinoma via network pharmacology.
Article in Translational gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gut microbiota plays a pivotal role in human homeostasis and health. This study adopted network pharmacology to clarify the metabolic transformation of gut microbiota metabolites and their molecular mechanisms in hepatocellular carcinoma (HCC) pathogenesis, aiming to unravel the complex crosstalk between gut microbiota, metabolites, and key genes. Methods: Gut microbiota metabolites and their associated genes were retrieved from the gutMGene database. Metabolite target genes were predicted using the SEA and STP databases, while HCC-related genes were compiled from GeneCards, OMIM, and CTD. Intersection analysis identified key genes mediating metabolite-regulated HCC progression. Core genes were screened via a protein-protein interaction (PPI) network, and comprehensive Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were further performed. A "microbiota-substrate-metabolite-target" network was constructed, and metabolites were evaluated for drug-likeness and toxicity to identify therapeutic candidates. Results: A total of 52 key genes involved in the gut microbiota-HCC interaction were screened, with Conclusions: Gut microbiota metabolites may exert regulatory effects on HCC mainly by targeting core genes. Targeting these genes in the regulatory network may offer a novel multidimensional therapeutic approach for HCC, and the identified metabolites could act as potential therapeutic candidates for HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.